Cadrenal Therapeutics, INC

Cadrenal Therapeutics is restructuring its clinical portfolio into a Cardiac Acute Critical Care Franchise and initiating a process to find strategic partners for its late-stage assets.

Cadrenal Therapeutics, Inc. has entered into a separation agreement with its Chief Medical Officer, James J. Ferguson III, who will resign effective July 31, 2026.

Cadrenal Therapeutics, Inc. reported the resignation of its Chief Medical Officer, James J. Ferguson III, effective July 31, 2026, and is currently seeking a replacement.

Cadrenal Therapeutics announced a private placement raising approximately $3 million through the sale of pre-funded warrants and common warrants, with net proceeds intended for working capital.

Cadrenal Therapeutics, Inc. has appointed John P. Sharp as Interim Chief Financial Officer and entered into a new Scope of Work with Lohman & Associates, Inc. for financial consulting services.

Cadrenal Therapeutics announced plans to seek FDA Rare Pediatric Disease Designation for tecarfarin in treating pediatric Kawasaki disease patients with coronary artery aneurysms, alongside a dual-track portfolio strategy.

Cadrenal Therapeutics reports a 35% reduction in net loss for Q1 2026, driven by decreased operating expenses, but faces substantial doubt regarding its ability to continue as a going concern.

Cadrenal Therapeutics reported a significant increase in net loss and cash burn for Q3 2025, raising substantial doubt about its ability to continue as a going concern without further financing.

Cadrenal Therapeutics reported a significant increase in net loss and cash burn for the first half of 2025, while advancing its lead drug candidate tecarfarin towards a Phase 3 clinical trial.

Cadrenal Therapeutics' Q1 2025 results show a widened net loss due to increased research and development and general and administrative expenses, despite ongoing efforts to advance its lead drug candidate, tecarfarin.

Cadrenal Therapeutics reported a net loss of $2.4 million for the third quarter of 2024, with increased operating expenses and ongoing development of their lead drug candidate, tecarfarin.

Cadrenal Therapeutics reported a net loss of $4.06 million for the first half of 2024 and highlighted the need for additional funding to continue operations.

Cadrenal Therapeutics reports increased losses and a significant cash burn in its 2025 annual report, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidate CAD-1005 towards a pivotal Phase 3 trial.

Cadrenal Therapeutics' 2024 annual report highlights the company's focus on developing tecarfarin for rare cardiovascular conditions and its recent collaboration with Abbott.

Cadrenal Therapeutics' 2023 annual report highlights the company's focus on developing tecarfarin for rare cardiovascular conditions, while also detailing financial results and risks.

Quang Pham, Chairman and CEO of Cadrenal Therapeutics, Inc., reported the sale of 7,400 shares of common stock under a Rule 10b5-1 trading plan.

Quang Pham, Director and Officer of Cadrenal Therapeutics, reports sale of common stock under a Rule 10b5-1 trading plan.

Quang X. Pham, Director and Officer of Cadrenal Therapeutics, Inc., reported the sale of common stock totaling 11,444 shares on June 22-23, 2026, under a Rule 10b5-1 trading plan.

Quang X. Pham, Director and Officer of Cadrenal Therapeutics, Inc., reported the sale of 3,613 shares of common stock on June 16, 2026, and 513 shares on June 17, 2026, under a Rule 10b5-1 trading plan.

Cadrenal Therapeutics Chairman and CEO Quang Pham sold 18,124 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Chairman and CEO Quang Pham sold 22,385 shares of common stock across three days in June 2026.

Cadrenal Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, equity plan amendments, and warrant exercise approval.

Cadrenal Therapeutics, Inc. has filed definitive additional materials outlining proposals for its upcoming stockholder meeting, including director election and auditor ratification.

Cadrenal Therapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on September 24, 2025, to vote on the election of a Class III director and the ratification of its independent registered public accounting firm.

Cardenal Therapeutics is asking stockholders to vote on key proposals including a reverse stock split, an increase in authorized shares, and amendments to their equity incentive plan at the upcoming annual meeting.

Cadrenal Therapeutics is asking stockholders to approve a reverse stock split, an increase in authorized shares, and an amendment to its equity incentive plan at the upcoming annual meeting.

Cadrenal Therapeutics filed an S-1 registration statement for the resale of 428,227 common shares underlying warrants from a recent private placement and registered direct offering.

Cadrenal Therapeutics, Inc.'s CEO and Chairman, Quang X. Pham, along with a related trust, has disclosed a combined beneficial ownership of 23.6% of the company's common stock, indicating a strong insider commitment and potential strategic initiatives.

Three Czech Republic-based entities, Havlickova 648 a.s., Dubnica Property s.r.o., and Miroslav Dornak, have filed an amended Schedule 13G disclosing a collective beneficial ownership of 4.39% in Cadrenal Therapeutics, Inc.

John Raymond Murphy, an insider at Cadrenal Therapeutics, Inc., has filed an amended Schedule 13G, disclosing beneficial ownership of 2.96% of the company's common stock as of December 31, 2024.